CERVOMED INC. - COMMON STOCK

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 يوليو 2024 08:51:12 بحسب Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Appoint William Elder as Chief Financial Officer

20 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the BIO CEO and Investor Conference

21 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 67

05 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 66

05 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire